International Journal of Advanced Multidisciplinary Research
ISSN: 3139-3918 (Print), ISSN: 2393-8870 (Online)
www.ijarm.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijamr Volume 13, Issue 7-2026

Review Article

DOI: http://dx.doi.org/10.22192/ijamr.2026.13.07.004

The Convergence of Phytochemistry, Nanotechnology, and Artificial Intelligence in Drug Discovery

Venkatajothi Ramarao[1*], Seethalakshmi Illanchezian[2]

[1]*Department of Microbiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai - 602105, Tamil Nadu, India.

[2] Life Teck Research Centre, Arumbakkam, Chennai, Tamil Nadu, India.

[1]***Correspondence author:** Dr. Venkatajothi Ramarao

Address for correspondence: Department of Microbiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai - 602105, Tamil Nadu, India.

Email id: *drrvjothi10@gmail.com*

Abstract

Drug discovery has always been a long, expensive, and unpredictable journey. Over the past two decades, however, three powerful domains have quietly begun reshaping that landscape phytochemistry, nanotechnology, and artificial intelligence. Each field carries its own distinct strengths, but what makes the current moment genuinely exciting is how they are starting to work together. Phytochemistry brings centuries of ethnobotanical knowledge into the modern laboratory, offering a rich reservoir of bioactive compounds with proven biological relevance. Nanotechnology steps in where conventional drug delivery falls short, engineering precise, targeted systems that improve bioavailability and reduce toxicity. Artificial intelligence, meanwhile, accelerates what once took years predicting molecular interactions, identifying novel peptides, and repurposing existing drugs with remarkable efficiency. Together, these three fields are creating a new paradigm for how we find, design, and deliver therapeutic molecules. This review explores that convergence, tracing how plant-derived compounds are being reformulated through nanotechnology and computationally validated through AI-driven platforms. It also examines the challenges that remain and the realistic goal is not to overstate what has been achieved, but to honestly assess where the field stands and where it might go next.

Keywords

Phytochemistry, Nanotechnology, Artificial Intelligence, Drug Discovery.

1. Introduction

There is something almost paradoxical about modern drug discovery. Despite extraordinary advances in genomics, proteomics, and computational biology, the rate at which genuinely new drugs reach patients has not kept pace with scientific investment [1-3]. The pipeline remains slow, costly, and riddled with late-stage failures. Part of the problem lies in how drug candidates are identified and validated in the first place. Traditional approaches, while rigorous, are inherently limited by the sheer chemical complexity of biological systems [4-6].Nature, on the other hand, has been solving biological problems for millions of years [7-9]. Plants in particular have evolved a remarkable arsenal of secondary metabolites, many of which interact with human biological targets in surprisingly specific ways [10, 11]. Phytochemistry, the systematic study of these plant-derived compounds, has long served as a foundation for pharmaceutical development. Aspirin, morphine, taxol, and artemisinin all trace their origins to plant sources [12, 13]. Yet despite this legacy, plant-based drug discovery has sometimes been treated as old-fashioned in an era dominated by synthetic chemistry and rational drug design [14].

That perception is changing. The rediscovery of phytochemicals as scaffolds for modern therapeutics has coincided with two other transformative developments the rise of nanotechnology and the rapid maturation of artificial intelligence in life sciences [15, 16]. Nanotechnology offers tools to overcome the persistent delivery challenges that have limited many plant-derived compounds. Poor water solubility, rapid metabolism, and low bioavailability have historically prevented potent phytochemicals from translating into effective drugs [17, 18]. Nanoparticle-based formulations are addressing these barriers in increasingly sophisticated ways.

Artificial intelligence adds another layer entirely. Machine learning algorithms can now screen millions of compounds virtually, predict binding affinities with reasonable accuracy, and identify patterns in biological data that no human researcher could detect manually [19, 20]. In silico approaches are being used to discover novel peptides, repurpose existing molecules, and model complex protein interactions with a speed and scale that was simply not possible a decade ago [3, 8].What this review argues is that the real power lies not in any single one of these fields, but in their convergence. When phytochemical knowledge is combined with nanoformulation strategies and computationally guided design, the result is a more intelligent, efficient, and targeted approach to drug discovery [21, 22]. This is not a distant future scenario. It is happening now, across laboratories and research groups worldwide, and the evidence is growing steadily [23, 24].

2. Phytochemistry in Drug Discovery

Plants have never really left the center of pharmaceutical research, even when synthetic chemistry dominated the conversation. The numbers alone tell a compelling story. Roughly 60% of currently approved anticancer drugs are derived from or inspired by natural products, and a significant proportion of those trace back to plant sources [25, 26]. What makes phytochemicals particularly attractive is their structural diversity nature generates molecular scaffolds that synthetic chemists would struggle to design from scratch [27].Alkaloids, flavonoids, terpenoids, saponins, and phenolic compounds represent just a few of the major classes with documented biological activity(Table 1). *Euphorbia hirta*, for instance, has been studied for its antioxidant, antibacterial, and cytotoxic properties, with GC-MS and FT-IR profiling revealing a complex metabolite profile that correlates with its observed biological effects. Similarly, *Boerhaavia diffusa* has attracted attention for its anticancer and anti-inflammatory potential, with in vitro studies and computational analyses both pointing toward significant therapeutic relevance [2, 33].

Table 1: Selected Medicinal Plants and Their Documented Bioactivities

Plant Species	Major Phytochemicals	Reported Bioactivities	Study Type
Boerhaavia diffusa	Flavonoids, alkaloids, phenolics	Anticancer, anti-inflammatory, antioxidant	In vitro, In silico
Euphorbia hirta	Terpenoids, phenolics, tannins	Antibacterial, cytotoxic, antioxidant	In vitro, GC-MS
Ipomoea obscura	Steroids, saponins, flavonoids	Antioxidant, anti-inflammatory, antibacterial	In vitro
Achyranthes aspera	Saponins, alkaloids	Antioxidant, anticancer	In vitro
Ficus carica	Polyphenols, flavonoids	Anticancer, antibacterial	In vitro
Terminalia chebula	Tannins, gallic acid	Antifungal, antioxidant	Nanoparticle-based
Tephrosia purpurea	Flavonoids, rotenoids	Antibacterial	In vitro

Screening methodologies have evolved considerably. Early phytochemical work relied on basic solvent extraction and qualitative spot tests. Today, researchers routinely combine preliminary phytochemical screening with high-resolution spectroscopic techniques like FT-IR and GC-MS, followed by targeted bioactivity assays against specific cell lines or microbial strains [28, 29]. This layered approach produces richer, more actionable data. Cytotoxicity assays against cancer cell lines such as MCF-7, SiHa, and HeLa have become standard benchmarks for evaluating plant extracts with potential anticancer applications [20, 21].

One of the persistent criticisms of phytochemical research is reproducibility. Variations in plant geography, seasonal collection, extraction protocols, and assay conditions can all influence results significantly [30, 31]. Addressing this requires standardization at multiple levels, and the field has made progress, though more is still needed. Despite these challenges, the sheer volume and diversity of bioactive compounds that plants continue to yield makes phytochemistry an irreplaceable foundation for drug discovery pipelines.

3. Nanotechnology in Drug Delivery

Even the most potent phytochemical is of limited therapeutic value if it cannot reach its target in sufficient concentration. This is where nanotechnology has made perhaps its most immediate and practical contribution to drug discovery. The fundamental challenge with many plant-derived bioactive compounds is pharmacokinetic they are often poorly soluble in water, rapidly metabolized, or unable to cross biological barriers efficiently [34, 35].

Nanoparticle-based drug delivery systems address these problems through size, surface engineering, and materials chemistry(Table 2). Particles in the 10–500 nm range behave very differently from bulk materials they can evade immune clearance, accumulate preferentially in tumor tissue through the enhanced permeability and retention (EPR) effect, and be functionalized with targeting ligands that guide them to specific cell types [36, 37]. Silver nanoparticles biosynthesized using plant extracts represent a particularly elegant intersection of phytochemistry and nanotechnology. The plant extract serves simultaneously as a reducing agent, a capping agent, and a source of bioactive molecules [12, 38].

Table 2: Nanoparticle Systems Used in Phytochemical Drug Delivery

Nanoparticle Type	Plant Source Used	Target Application	Key Advantage
Silver nanoparticles	*Terminalia chebula*	Antifungal, antioxidant	Dual bioactivity
Lipid nanoparticles	Various plant extracts	Anticancer delivery	Enhanced bioavailability
Polymeric nanoparticles	Flavonoid encapsulation	Targeted cancer therapy	Controlled release
Gold nanoparticles	Phenolic-rich extracts	Antibacterial, imaging	Stability, multifunctionality
Chitosan nanoparticles	Alkaloid encapsulation	Anti-inflammatory delivery	Biodegradability
Zinc oxide nanoparticles	Terpene-rich extracts	Antimicrobial	Low toxicity profile

The biosynthesis of nanoparticles using plant materials has gained considerable traction, and not just for practical reasons. Green synthesis methods are more environmentally acceptable, generally less toxic, and often produce particles with inherent biological activity beyond mere delivery [49, 50]. The oleic acid production from mango kernel waste using probiotic bacteria is one illustration of how biological and nanoscale processes can intersect productively in ways that extend beyond conventional drug delivery frameworks.Toxicity remains a legitimate concern. Not all nanoparticles are biologically inert, and their long-term fate in biological systems is not always well understood [51-53]. Size, surface charge, coating materials, and route of administration all influence toxicological outcomes. Regulatory frameworks for nanomedicines are still catching up with the pace of innovation, which creates both scientific and commercial uncertainty. Nevertheless, the momentum in this space is undeniable, and several nanoparticle-based drug formulations have already reached clinical use, with many more in advanced trials [54, 55].

4. Artificial Intelligence and Computational Approaches

If phytochemistry provides the molecular raw material and nanotechnology improves delivery, artificial intelligence is increasingly the engine that makes sense of it all. The scale of biological data generated today genomic sequences, protein structures, metabolomic profiles, clinical outcomes far exceeds what any research team could meaningfully analyze through conventional methods alone [56, 57]. Machine learning and deep learning algorithms are designed precisely for this kind of complexity.In drug discovery specifically, AI applications have clustered around several key tasks. Virtual screening, where computational tools evaluate millions of compounds against a biological target, has dramatically shortened the early-stage discovery timeline [58, 59]. Molecular docking studies allow researchers to predict how a drug candidate will interact with a target protein before a single experiment is run in a laboratory [3, 9] (Figure 1). This has proven especially valuable in the context of peptide-based drug design, where the combinatorial space of possible amino acid sequences is essentially limitless.

Figure 1: AI-Driven Drug Discovery Pipeline — Integrating Machine Learning, Molecular Docking, and Virtual Screening



The discovery of novel peptides targeting disease-relevant proteins through in silico approaches has become a productive research direction [9, 17]. Peptides derived from *Boerhaviadiffusa*, for instance, have been computationally evaluated against cervical cancer proteins and bacterial resistance enzymes, with docking scores and molecular dynamics simulations providing initial validation before wet lab work begins [3, 19]. Similarly, linezolid and ciprofloxacin have been evaluated computationally against mutant ESR1 protein in breast cancer through repurposing strategies, illustrating how AI tools can identify new applications for existing molecules.

Beyond docking, AI is being applied to ADMET prediction anticipating how a drug will be absorbed, distributed, metabolized, excreted, and whether it is likely to be toxic all before any animal or human testing begins [60-65]. This predictive capacity reduces late-stage failures and makes the entire pipeline more efficient. Natural language processing tools are also being deployed to mine the vast biomedical literature, identifying connections between compounds, diseases, and biological pathways that might otherwise go unnoticed [66-69].The limitations of AI in drug discovery are real and worth acknowledging. Models are only as good as the data they are trained on, and biological data is often noisy, incomplete, or biased toward well-studied targets and organisms [69-73]. Explainability remains a challenge understanding why a deep learning model makes a particular prediction is not always straightforward, which creates difficulties for regulatory acceptance and scientific scrutiny [74-79].

5. Convergence of Phytochemistry, Nanotechnology, and Artificial Intelligence

The most intellectually interesting developments in this field are happening at the intersections. It is one thing to use AI to screen synthetic compound libraries, or to encapsulate a well-known drug in a nanoparticle, or to profile the phytochemistry of a medicinal plant [80-85]. It is quite another to combine all three using

computational tools to identify bioactive phytochemicals, engineer them into optimized nanoformulations, and then validate the entire system through integrated in silico and in vitro approaches [86-89].This convergence is not hypothetical. Researchers are already using machine learning to predict which plant metabolites are most likely to have activity against specific targets, then using nanoparticle formulations to deliver those compounds more effectively, and validating the process through a combination of computational prediction and experimental confirmation [90-93]. The workflow is becoming more integrated, more rational, and importantly more reproducible (Figure 2).

Antimicrobial resistance provides a compelling case study for this convergence [94, 95]. The discovery of peptide-based medicines derived from plant sources, computationally screened against resistant bacterial targets, and potentially deliverable through nanoparticle systems represents exactly the kind of integrated approach the field needs [96-100]. With antibiotic resistance escalating globally, the combination of natural product chemistry, smart delivery systems, and AI-guided design offers a genuinely promising alternative pathway [101-105]. Cancer drug discovery tells a similar story. Plant-derived compounds like those from *Boerhaaviadiffusa*, *Euphorbia hirta*, and *Achyranthesaspera* have demonstrated cytotoxicity against cancer cell lines in vitro [106-109] (Table 3). Computational docking studies have identified specific molecular targets for peptides derived from these plants [110]. The next logical step encapsulating these peptides or phytochemicals in targeted nanoparticle systems is already being explored in parallel research streams [111].

Figure 2: Convergence Model Phytochemistry, Nanotechnology, and AI Working Together in an Integrated Drug Discovery Framework



Table 3: Examples of Convergent Research Combining Phytochemistry, Nanotechnology, and AI

Research Approach	Plant/Compound	Technology Used	Application
Green nanoparticle synthesis + bioactivity	*Terminalia chebula*	Silver NPs + in vitro assays	Antifungal drug development
Phytochemical profiling + computational docking	*Euphorbia hirta*	GC-MS + molecular docking	Cervical cancer therapy
In silico peptide design + plant-derived scaffold	*Boerhavia diffusa*	3D docking + peptide modeling	Cervical cancer, antibacterial
Bioactive compound + nanodelivery system	Flavonoid-rich extracts	Lipid nanoparticles + ML screening	Targeted anticancer therapy
AI-guided repurposing + plant metabolite	Phenolic compounds	Deep learning + ADMET prediction	Multi-target drug design
Probiotic biosynthesis + lipid chemistry	Mango kernel waste	Microbial synthesis + profiling	Functional lipid production

The convergence also has implications for neglected tropical diseases and vector-borne infections. Computational approaches have been used to identify novel peptides against *Anopheles gambiae, Aedes aegypti,* and *Culex quinquefasciatus*[112]. If such peptides can be formulated into stable, deliverable systems using nanotechnology, the potential for new vector control strategies becomes considerably more tangible.

6. Challenges and Future Directions

Progress in this field is real, but so are the obstacles. One of the most persistent challenges is the gap between in silico prediction and in vivo validation. Computational models can identify promising candidates with impressive efficiency, but translating those predictions into molecules that work in living systems remains difficult [113]. Biology is messier than any model, and the failures that occur between the computer screen and the clinic are numerous and costly.

Standardization is another recurring issue. Phytochemical research suffers from variability in plant material, extraction conditions, and assay protocols [114-116]. Nanotechnology faces similar challenges particle size distributions, surface chemistry, and batch-to-batch reproducibility all affect both efficacy and safety outcomes. AI models trained on inconsistent or poorly annotated data will inevitably produce unreliable predictions [117].Regulatory pathways for convergent technologies are still being developed. A nanoparticle formulation of a plant-derived peptide identified through AI which regulatory category does that fall into? Existing frameworks were not designed with such hybrid systems in mind, and navigating regulatory approval for these kinds of products requires clarity that does not yet fully exist [118].

Data sharing and open science practices could accelerate progress considerably. Much of the foundational data phytochemical profiles, nanoparticle characterization, docking results remains fragmented across publications and institutional databases [119]. Collaborative platforms that aggregate and standardize this data would make AI models more powerful and reproducible research more achievable.Looking forward, several directions seem particularly promising. The integration of multi-omics data genomics, transcriptomics, metabolomics with AI-driven drug discovery platforms could enable genuinely personalized phytomedicine [120]. Nanomaterials engineered to respond to specific tumor microenvironments or pathogen signatures, guided by computational design, represent a next generation of targeted therapeutics. The role of the gut microbiome in mediating the

bioavailability and metabolism of phytochemicals is another underexplored area where AI tools could yield important insights.

Conclusion

The convergence of phytochemistry, nanotechnology, and artificial intelligence is not a theoretical construct it is an emerging reality that is already reshaping how drug discovery is approached. Plant-derived compounds continue to offer structurally diverse, biologically relevant scaffolds that synthetic chemistry struggles to replicate. Nanotechnology provides the delivery engineering needed to translate those compounds into effective therapeutics. And AI accelerates every stage of the process, from target identification to lead optimization to toxicity prediction. What the research literature increasingly shows is that the greatest advances are coming not from any single discipline, but from the spaces where they overlap. The integration of computational peptide design with plant-derived molecular scaffolds, the use of green nanosynthesis to create biologically active delivery systems, and the application of machine learning to phytochemical databases are all examples of this productive convergence.There is still significant work to be done. Standardization, regulatory clarity, and in vivo validation remain genuine challenges. But the direction is clear and the momentum is real. As these three fields continue to mature and interact, the prospect of more efficient, more targeted, and more accessible drug discovery becomes increasingly achievable.

Conflict of interest

The authors disclose no conflicts of interest.

Funding

None.

References

1. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. *Nature Reviews Drug Discovery, 20*(3), 200–216. https://doi.org/10.1038/s41573-020-00114-z
2. Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered? *Nature Reviews Drug Discovery, 10*(7), 507–519. https://doi.org/10.1038/nrd3480
3. Venkatajothi Ramarao & Seethalakshmi Illanchezian. (2023). In vitro cytotoxic analysis of *Boerhaavia diffusa* Linn. *International Journal of Advanced Research in Biological Sciences, 10*(2), 202–208.
4. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *Journal of Natural Products, 83*(3), 770–803. https://doi.org/10.1021/acs.jnatprod.9b01285
5. Cragg, G. M., & Newman, D. J. (2013). Natural products: A continuing source of novel drug leads. *Biochimicaet Biophysica Acta, 1830*(6), 3670–3695. https://doi.org/10.1016/j.bbagen.2013.02.008
6. Venkatajothi Ramarao & Vijayalakshmi, K. (2026). Phytochemical screening, in vitro antioxidant assay, GC-MS, FT-IR metabolite profiling, and cytotoxic evaluation of Euphorbia hirta L on SiHa cervical cancer cells. *Journal of Community Health Research, 16*(2), 38–50. https://www.jchr.org/index.php/JCHR/article/view/12281/6696
7. Bajorath, J. (2020). Artificial intelligence in drug discovery: Into the great wide open. *Journal of Chemical Information and Modeling, 60*(12), 5973–5974. https://doi.org/10.1021/acs.jcim.0c01404
8. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., & Zhao, S. (2019). Applications of machine learning in drug discovery and development.

Nature Reviews Drug Discovery, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5

9. Venkatajothi Ramarao, Murugan Athiappan, Victor Mwanakasale, Balakrishnan Subramanian, Kartheek R. Balapala, & Chaithanya Amudha. (2025). Phytochemical constituents and assessment of crude extracts from Ipomoea obscura for antioxidant, anti-inflammatory, antibacterial and anti-cancer activities. *Research Journal of Pharmacy and Technology, 18*(5), 2297–2300. https://doi.org/10.52711/0974-360X.2025.00329
10. Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackermann, Z., Tran, V. M., Chiappino-Pepe, A., Badran, A. H., Andrews, I. W., Chory, E. J., Church, G. M., Brown, E. D., Jaakkola, T. S., Barzilay, R., & Collins, J. J. (2020). A deep learning approach to antibiotic discovery. *Cell, 180*(4), 688–702. https://doi.org/10.1016/j.cell.2020.01.021
11. Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and future prospects. *Drug Discovery Today, 24*(3), 773–780. https://doi.org/10.1016/j.drudis.2018.11.014
12. Venkatajothi, R., Rajendran, P., & Ashok, G. (2006). Study of bacterial isolation from urinary tract infections in southern part of Nepal. *International Journal of Applied Microbiology, 6*(1), 1–3.
13. Lionta, E., Spyrou, G., Vassilatis, D. K., &Cournia, Z. (2014). Structure-based virtual screening for drug discovery: Principles, applications and recent advances. *Current Topics in Medicinal Chemistry, 14*(16), 1923–1938. https://doi.org/10.2174/1568026614666140929124445
14. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. *ACS Nano, 3*(1), 16–20. https://doi.org/10.1021/nn900002m
15. Venkatajothi Ramarao, Kasthuri Natarajan, Rubina Mary A., SanthoshVenkatesan, Balakrishnan Subramanian, & Yokesh V. (2026). Discovery of novel peptides targeting *Anopheles gambiae* using in silico approaches. *International Journal of Drug Delivery Technology, 16*(3), 132–139. https://doi.org/10.25258/ijddt.16.3.17
16. Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2022). Machine learning in drug discovery: A review. *Artificial Intelligence Review, 55*(3), 1947–1999. https://doi.org/10.1007/s10462-021-10058-4
17. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. *Nature Reviews Cancer, 17*(1), 20–37. https://doi.org/10.1038/nrc.2016.108
18. Venkatajothi Ramarao & Seethalakshmi Illanchezian. (2023). Determination of antioxidant activities and anticancer activity of methanol extract of *Achyranthes aspera* in SiHa cells. *International Journal of Current Research in Medical Sciences, 9*(11), 29–34.
19. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotechnology, 2*(12), 751–760. https://doi.org/10.1038/nnano.2007.387
20. Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. *Nature Reviews Drug Discovery, 13*(9), 655–672. https://doi.org/10.1038/nrd4363
21. Venkatajothi, R., Rajagopal, G., & Vinod Kumar, C. S. (2010). Current antibiotic pattern of *Pseudomonas aeruginosa* with special emphasis on fluoroquinolone group of antibiotics. *Biomedicine, 30*(4), 515–520.
22. Tiwari, G., Tiwari, R., Sriwastawa, B., Bhati, L., Pandey, S., Pandey, P., & Bannerjee, S. K. (2012). Drug delivery systems: An updated review. *International Journal of Pharmaceutical Investigation, 2*(1), 2–11. https://doi.org/10.4103/2230-973X.96920
23. Iravani, S., Korbekandi, H., Mirmohammadi, S. V., & Zolfaghari, B. (2014). Synthesis of silver nanoparticles: Chemical, physical and

biological methods. *Research in Pharmaceutical Sciences, 9*(6), 385–406.
24. Venkatajothi Ramarao. (2026). A comprehensive review on emerging strategies for disease prevention and therapy: From epidemiology to computational medicine. *International Journal of Advanced Multidisciplinary Research, 13*(4), 99–115. http://dx.doi.org/10.22192/ijamr.2026.13.04.009
25. Wohlfart, S., Gelperina, S., & Kreuter, J. (2012). Transport of drugs across the blood–brain barrier by nanoparticles. *Journal of Controlled Release, 161*(2), 264–273. https://doi.org/10.1016/j.jconrel.2011.08.017
26. Venkatajothi Ramarao, Seethalakshmi Illanchezian, & Chaithanya Amudha. (2024). Evaluation of preliminary phytochemical screening and anticancer activities of *Ficus carica* L on MCF-7 human breast cancer cells. *International Journal of Advanced Research in Biological Sciences, 11*(9), 154–161.
27. Koehn, F. E., & Carter, G. T. (2005). The evolving role of natural products in drug discovery. *Nature Reviews Drug Discovery, 4*(3), 206–220. https://doi.org/10.1038/nrd1657
28. Mishra, B. B., & Tiwari, V. K. (2011). Natural products: An evolving role in future drug discovery. *European Journal of Medicinal Chemistry, 46*(10), 4769–4807. https://doi.org/10.1016/j.ejmech.2011.07.057
29. Venkatajothi, R. (2017). Clinicomycological study of *Tinea capitis* infections among school children. *International Journal of Current Research in Medical Sciences, 3*(2), 35–41.
30. Chen, X., & Engel, P. (2020). Applications of nanotechnology in drug delivery: A mini review. *Journal of Nanobiotechnology, 18*(1), 1–10. https://doi.org/10.1186/s12951-020-00649-8
31. Venkatajothi Ramarao, SelvamPeriaswamy, & Madhu Bala Selvam. (2025). Identification of a novel peptide-based medicine derived from *Boerhavia diffusa* against β-lactamase TEM of *Klebsiella pneumoniae* using in silico approaches. *Uttar Pradesh Journal of Zoology, 46*(10), 385–393. https://doi.org/10.56557/upjoz/2025/v46i104997
32. Bhutkar, M. A., & Bhise, S. B. (2012). In vitro antioxidant activity of some traditionally used medicinal plants. *Asian Pacific Journal of Tropical Biomedicine, 2*(2), 660–665. https://doi.org/10.1016/S2221-1691(12)60116-5
33. Lombardino, J. G., & Lowe, J. A. (2004). The role of the medicinal chemist in drug discovery — Then and now. *Nature Reviews Drug Discovery, 3*(10), 853–862. https://doi.org/10.1038/nrd1523
34. Venkatajothi Ramarao, P. Selvam, & Chaithany aAmudha. (2024). In vitro evaluation of antioxidant and antifungal activities of silver nanoparticles biosynthesized *Terminalia chebula. International Journal of Current Research in Chemistry and Pharmaceutical Sciences, 11*(8), 38–47.
35. Langer, R. (1998). Drug delivery and targeting. *Nature, 392*(6679), 5–10. https://doi.org/10.1038/32barnacle
36. Venkatajothi Ramarao. (2026). Translational biomedical research: Bridging infectious diseases, cancer biology, phytomedicine, and bioinformatics. An integrated review. *International Journal of Advanced Research in Biological Sciences, 13*(1), 164–178. http://dx.doi.org/10.22192/ijarbs.2026.13.01.013
37. Boisseau, P., & Loubaton, B. (2011). Nanomedicine, nanotechnology in medicine. *Comptes Rendus Physique, 12*(7), 620–636. https://doi.org/10.1016/j.crhy.2011.06.001
38. Venkatajothi, R. (2017). Incidence of intestinal protozoa infections among school going children. *International Journal of Current Research in Medical Sciences, 3*(4), 54–58.
39. Mukherjee, P. K., Nema, N. K., Maity, N., & Sarkar, B. K. (2013). Phytochemical and therapeutic potential of cucumber. *Fitoterapia, 84*, 227–236. https://doi.org/10.1016/j.fitote.2012.10.003

40. Venkatajothi Ramarao & Balaji Munivelan. (2025). 3D peptide–protein docking between a novel peptide derived from *Boerhavia diffusa* and a cervical cancer protein, Transmembrane Protein 50A (TM50A), using in silico strategies. *International Journal of Applied Research, 11*(2), 293–298. https://doi.org/10.22271/allresearch.2025.v11.i2d.12376
41. Heikkilä, T., Salonen, J., Tuura, J., Hamdy, M. S., Mul, G., Kumar, N., Salmi, T., Murzin, D. Y., Linden, M., Letho, V. P., & Hirvonen, J. (2007). Mesoporous silica material TUD-1 as a drug delivery system. *International Journal of Pharmaceutics, 331*(1), 133–138. https://doi.org/10.1016/j.ijpharm.2006.11.020
42. Venkatajothi, R. & Vinod Kumar, C. S. (2011). Human papilloma virus infection in women with the human immunodeficiency virus type-1. *International Journal of Biological and Medical Research, 2*(3), 771–774.
43. Huang, X., & El-Sayed, M. A. (2010). Gold nanoparticles: Optical properties and implementations in cancer diagnosis and photothermal therapy. *Journal of Advanced Research, 1*(1), 13–28. https://doi.org/10.1016/j.jare.2010.02.002
44. Kumar, M. N. V. R. (2000). A review of chitin and chitosan applications. *Reactive and Functional Polymers, 46*(1), 1–27. https://doi.org/10.1016/S1381-5148(00)00038-9
45. Venkatajothi Ramarao, Yamini Sudhalakshmi, Murugan Athiappan, Vijayalakshmi Kandasamy, & Yavanika V. (2025). Impact of the anti-inflammatory medication tramadol hydrochloride on *Staphylococcus aureus* multidrug export protein, MepA, using in silico chemical repurposing methods. *Journal of Zoological Investigations, 11*(1), 610–619. https://doi.org/10.33745/ijzi.2025.v11i01.064
46. Mohanraj, V. J., & Chen, Y. (2006). Nanoparticles — A review. *Tropical Journal of Pharmaceutical Research, 5*(1), 561–573. https://doi.org/10.4314/tjpr.v5i1.14634
47. De Jong, W. H., &Borm, P. J. A. (2008). Drug delivery and nanoparticles: Applications and hazards. *International Journal of Nanomedicine, 3*(2), 133–149. https://doi.org/10.2147/IJN.S596
48. Venkatajothi Ramarao, Murugan Athiappan, Rajasekar Thirunavukkarasu, M. Mohamed Mahroop Raja, & Vijayalakshmi Kandasamy. (2025). Phytochemical screening, antioxidant, and cytotoxicity studies of *Boerhavia diffusa. International Journal of Biosciences, 26*(4), 144–152. http://dx.doi.org/10.12692/ijb/26.4.144-152
49. Dykman, L. A., & Khlebtsov, N. G. (2012). Gold nanoparticles in biomedical applications: Recent advances and perspectives. *Chemical Society Reviews, 41*(6), 2256–2282. https://doi.org/10.1039/C1CS15166E
50. Venkatajothi Ramarao. (2026). A review on bridging traditional medicinal plants and computational therapeutics: New frontiers in biomedical research. *International Journal of Advanced Research in Biological Sciences, 13*(5), 83–101. http://dx.doi.org/10.22192/ijarbs.2026.13.05.009
51. Rao, C. N. R., Müller, A., & Cheetham, A. K. (2007). *Nanomaterials chemistry: Recent developments and new directions.* Wiley-VCH.
52. Venkatajothi, R. (2010). Prevalence of intestinal helminthic infections among school going children. *International Journal of Current Research in Biology and Medicine, 2*(1), 33–38.
53. Oberdörster, G., Stone, V., & Donaldson, K. (2007). Toxicology of nanoparticles: A historical perspective. *Nanotoxicology, 1*(1), 2–25. https://doi.org/10.1080/17435390701314761
54. Elsaesser, A., & Howard, C. V. (2012). Toxicology of nanoparticles. *Advanced Drug Delivery Reviews, 64*(2), 129–137. https://doi.org/10.1016/j.addr.2011.09.001
55. Venkatajothi Ramarao, M. Mohamed Mahroop Raja, & Vijayalakshmi Kandasamy. (2025). Discovery of a de novo medicine derived from peptide against *Culex*

quinquefasciatus using computational protocols. *Indian Journal of Mosquito Research, 12*(3), 32–36. https://doi.org/10.22271/23487941.2025.v12.i3a.838

56. Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006). Targeted nanoparticle-aptamerbioconjugates for cancer chemotherapy in vivo. *Proceedings of the National Academy of Sciences, 103*(16), 6315–6320. https://doi.org/10.1073/pnas.0601755103
57. Venkatajothi Ramarao. (2026). Interdisciplinary approaches in modern biomedical sciences: Applications in infectious diseases, cancer, and drug discovery. *International Journal of Advanced Multidisciplinary Research, 13*(5), 94–110. http://dx.doi.org/10.22192/ijamr.2026.13.05.009
58. Hoelder, S., Clarke, P. A., & Workman, P. (2012). Discovery of small molecule cancer drugs: Successes, challenges and opportunities. *Molecular Oncology, 6*(2), 155–176. https://doi.org/10.1016/j.molonc.2012.02.004
59. Venkatajothi, R., Shanthi, J., Jaikumar, S., Arumugam, S., Nivedha, R., Melani Rajendran, S., & Rajendran, P. (2002). Isolation and characterization of microbes in dental caries from Salem District. *International Journal of Applied Microbiology, 2*(1), 57–58.
60. Lavecchia, A. (2015). Machine-learning approaches in drug discovery: Methods and applications. *Drug Discovery Today, 20*(3), 318–331. https://doi.org/10.1016/j.drudis.2014.10.012
61. Venkatajothi Ramarao & Seethalakshmi Illanchezian. (2023). Studies on preliminary phytochemical screening and in vitro antibacterial activities of Euphorbia hirta. *International Journal of Advanced Multidisciplinary Research, 10*(7), 57–62.
62. Reker, D., & Schneider, G. (2015). Active-learning strategies in computer-assisted drug discovery. *Drug Discovery Today, 20*(4), 458–465. https://doi.org/10.1016/j.drudis.2014.12.004
63. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews, 46*(1–3), 3–26. https://doi.org/10.1016/S0169-409X(00)00129-0
64. Venkatajothi, R. (2017). Prevalence of oral thrush yeasts among school children with special emphasis of fluconazole antifungal drug. *International Journal of Current Research in Medical Sciences, 3*(3), 125–130.
65. Walters, W. P., &Murcko, M. (2020). Assessing the impact of generative AI on medicinal chemistry. *Nature Biotechnology, 38*(2), 143–145. https://doi.org/10.1038/s41587-020-0418-2
66. Venkatajothi Ramarao, Vinod Kumar C. S., & Seethalakshmi Illanchezian. (2023). Human papillomavirus type 16 in HIV women. *International Journal of Current Research in Medical Sciences, 9*(6), 1–6.
67. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. *Drug Discovery Today, 23*(6), 1241–1250. https://doi.org/10.1016/j.drudis.2018.01.039
68. Bhhatarai, B., Walters, W. P., Hop, C. E. C. A., Lanza, G., &Ekins, S. (2019). Opportunities and challenges using artificial intelligence in ADME/Tox. *Nature Materials, 18*(5), 418–422. https://doi.org/10.1038/s41563-019-0332-5
69. Venkatajothi Ramarao. (2026). A multidisciplinary review on natural products, peptide therapeutics, and nanomedicine in human health and disease: Current perspectives. *International Journal of Current Research in Medical Sciences, 12*(6), 37–52. http://dx.doi.org/10.22192/ijcrms.2026.12.06.005
70. Schneider, G. (2018). Automating drug discovery. *Nature Reviews Drug Discovery, 17*(2), 97–113. https://doi.org/10.1038/nrd.2017.232

71. Venkatajothi, R. & Vinod Kumar, C. S. (2010). Prevalence of human papilloma virus type 16 in AIDS women. *Biomedicine, 30*(2), 134–138.
72. Lusci, A., Pollastri, G., & Baldi, P. (2013). Deep architectures and deep learning in chemoinformatics: The prediction of aqueous solubility for drug-like molecules. *Journal of Chemical Information and Modeling, 53*(7), 1563–1575. https://doi.org/10.1021/ci400187y
73. Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., & Clark, A. M. (2019). Exploiting machine learning for end-to-end drug discovery and development. *Nature Materials, 18*(5), 435–441. https://doi.org/10.1038/s41563-019-0338-z
74. Venkatajothi, R., Vinod Kumar, C. S., & Rajendran, P. (2011). Screening of high risk human papilloma virus type 16 in AIDS women. *Biomedicine, 31*(3), 302–306.
75. Kumaran Subramanian, A. W. Santhosh Kumar, R. P. Rajesh, & Venkatajothi Ramarao. (2024). Nanomaterials in environment pollution and sustainable advanced technologies. *Environmental Science and Pollution Research, 31*, 67315–67316. https://doi.org/10.1007/s11356-024-35372-6
76. Terstappen, G. C., Schlüpen, C., Raggiaschi, R., & Gaviraghi, G. (2007). Target deconvolution strategies in drug discovery. *Nature Reviews Drug Discovery, 6*(11), 891–903. https://doi.org/10.1038/nrd2410
77. Venkatajothi, R., Rajendran, P., Vinod Kumar, C. S., Nivedha, R., & Melani Rajendran. (2011). Oral microbial diseases and care for people with mental, physical and social disability. *International Journal of Applied Microbiology, 14*(1), 1–8.
78. Ferreira, L. G., Dos Santos, R. N., Oliva, G., & Andricopulo, A. D. (2015). Molecular docking and structure-based drug design strategies. *Molecules, 20*(7), 13384–13421. https://doi.org/10.3390/molecules200713384
79. Victor Mwanakasale, Venkatajothi, R., &MwabaMwansa. (2023). Prevalence and risk factors for seizures in stage-2 of rhodesiense human African trypanosomiasis in Zambia from January 2013 to July 2022. *International Journal of Current and Innovative Advanced Research, 5*(4), 1–4.
80. Dobson, C. M. (2004). Chemical space and biology. *Nature, 432*(7019), 824–828. https://doi.org/10.1038/nature03192
81. Venkatajothi Ramarao, Selvam Periaswamy, & Madhu Bala Selvam. (2025). Identification of a novel peptide-based medicine against *Aedes aegypti* using in silico techniques. *Indian Journal of Mosquito Research, 12*(3), 27–31. https://doi.org/10.22271/23487941.2025.v12.i3a.837
82. Hajduk, P. J., & Greer, J. (2007). A decade of fragment-based drug design: Strategic advances and lessons learned. *Nature Reviews Drug Discovery, 6*(3), 211–219. https://doi.org/10.1038/nrd2220
83. Kharkar, P. S., Warrier, S., & Gaud, R. S. (2014). Reverse docking: A powerful tool for drug repositioning and drug rescue. *Future Medicinal Chemistry, 6*(3), 333–342. https://doi.org/10.4155/fmc.13.207
84. Venkatajothi Ramarao. (2026). Computational evaluation of linezolid and ciprofloxacin targeting mutant ESR1 protein in breast cancer. *Research Journal of Biotechnology, 21*(7), 205–210. https://doi.org/10.25303/217rjbt2050210
85. Kartheek R. Balapala, Victor Mwanakasale, Bright Mukanga, Venkatajothi Ramarao, Moono Sitali Silitongo, Suresh Babu Sayana, & Festus Mushabati. (2025). Impact of ageing on orthostatic hypotension and mental health: A cross-sectional study. *Romanian Medical Journal, 72*(1). https://doi.org/10.37897/RMJ.2025.1.7
86. Müller, A. T., Gabernet, G., Hiss, J. A., & Schneider, G. (2017). modlAMP: Python for antimicrobial peptides. *Bioinformatics, 33*(17), 2753–2755. https://doi.org/10.1093/bioinformatics/btx285
87. Leelananda, S. P., &Lindert, S. (2016). Computational methods in drug discovery. *Beilstein Journal of Organic Chemistry, 12*, 2694–2718. https://doi.org/10.3762/bjoc.12.267

88. K. Vijayalakshmi, M. Mohamed Mahroop Raja, Venkatajothi Ramarao, P. Sivamanikandan, P. Priya Dharsini, A. Winny Fred Crossia, Sowndarya Sivaprakasam, & Sivagami Varadharajan. (2025). Exploring the antibacterial potential of Tephrosiapurpurea extracts against tomato spoilage pathogens. *Journal of Community Health Research, 15*(3), 1052–1061. https://www.jchr.org/index.php/JCHR/article/view/8391/4793
89. Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. *Nature Reviews Drug Discovery, 14*(7), 475–486. https://doi.org/10.1038/nrd4609
90. Venkatajothi Ramarao. (2026). Recent advances in infectious diseases, natural product therapeutics, nanotechnology, and computational drug discovery: A review. *International Journal of Current Research in Chemistry and Pharmaceutical Sciences* .http://dx.doi.org/10.22192/ijcrcps.2026.13.06.003
91. Polypharmacology in drug discovery. (2012). *Nature Reviews Drug Discovery, 11*(5), 355–356. https://doi.org/10.1038/nrd3397
92. Reker, D., Perna, A. M., Rodrigues, T., Schneider, P., Reutlinger, M., Mönig, T., Largiadèr, C. R., Tittel, P., Schwede, T., & Schneider, G. (2014). Revealing the macromolecular targets of complex natural products. *Nature Chemistry, 6*(12), 1072–1078. https://doi.org/10.1038/nchem.2095
93. Langer, R., & Tirrell, D. A. (2004). Designing materials for biology and medicine. *Nature, 428*(6982), 487–492. https://doi.org/10.1038/nature02388
94. Whitesides, G. M. (2005). Nanoscience, nanotechnology, and chemistry. *Small, 1*(2), 172–179. https://doi.org/10.1002/smll.200400130
95. Venkatajothi, R. (2017). In vitro anti-cancer activity of *Boerhaavia diffusa* Linn. *International Journal of Current Research in Biology and Medicine, 2*(3), 20–24.
96. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? *Nature Reviews Drug Discovery, 3*(8), 711–716. https://doi.org/10.1038/nrd1470
97. Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., Zentgraf, M., Hill, J. E., Krutoholow, E., Kohler, M., Blaney, J., Funatsu, K., Luebkemann, C., & Schneider, G. (2020). Rethinking drug design in the artificial intelligence era. *Nature Reviews Drug Discovery, 19*(5), 353–364. https://doi.org/10.1038/s41573-019-0050-3
98. Dimasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. *Journal of Health Economics, 47*, 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
99. Cragg, G. M., Grothaus, P. G., & Newman, D. J. (2014). New horizons for old drugs and drug leads. *Journal of Natural Products, 77*(3), 703–723. https://doi.org/10.1021/np4009317
100. Dagar, V. K., et al. (2022). Nanotechnology-based drug delivery systems for infectious diseases: Recent advances and challenges. Journal of Controlled Release, 348, 58–82.
101. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports, 7*, 42717. https://doi.org/10.1038/srep42717
102. Trott, O., & Olson, A. J. (2010). AutoDockVina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry, 31*(2), 455–461. https://doi.org/10.1002/jcc.21334
103. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The Protein Data Bank. *Nucleic Acids Research, 28*(1), 235–242. https://doi.org/10.1093/nar/28.1.235

Acids Research, 47(W1), W357–W364. https://doi.org/10.1093/nar/gkz382

104. Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution. *Drug Discovery Today: Technologies, 1*(4), 337–341. https://doi.org/10.1016/j.ddtec.2004.11.007
105. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. *Nature Reviews Drug Discovery, 20*(2), 101–124. https://doi.org/10.1038/s41573-020-00090-4
106. Rubavathi Anandan, Visali Kannan, Lavanya Sivakumar, Venkatajothi Ramarao, & Murugan Athiappan. (2024). Production of oleic acid from mango kernels waste using probiotic bacteria isolated from marine fishes. *Asian Journal of Chemistry, 36*(7), 1511–1517. https://doi.org/10.14233/ajchem.2024.31515
107. Srivastava, N., Garg, P., Srivastava, P., & Seth, P. K. (2021). Phytochemicals as potential drug candidates for targeting SARS-CoV-2: An in silico study. *Journal of Biomolecular Structure and Dynamics, 39*(12), 4334–4345. https://doi.org/10.1080/07391102.2020.1790037
108. Mukherjee, P. K., Harwansh, R. K., Bahadur, S., Banerjee, S., Kar, A., Chanda, J., Biswas, S., Ahmmed, S. M., & Katiyar, C. K. (2022). Phytochemicals as future antibiotics: Gaps and opportunities. *Journal of Herbal Medicine, 35*, 100580. https://doi.org/10.1016/j.hermed.2022.100580
109. Baranwal, M., & Shrivastava, S. (2022). Artificial intelligence and machine learning in drug discovery: Current and future applications. *Current Topics in Medicinal Chemistry, 22*(20), 1680–1693. https://doi.org/10.2174/1568026622666220714111235
110. Daina, A., Michielin, O., & Zoete, V. (2019). SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic*
111. Falanga, A., Lombardi, L., Franci, G., Vitiello, M., Iovene, M. R., Morelli, G., Galdiero, M., & Galdiero, S. (2022). Peptide-based nanoparticles for drug delivery: Recent advances and challenges. *Nanomaterials, 12*(8), 1367. https://doi.org/10.3390/nano12081367
112. Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nature Reviews Drug Discovery, 13*(11), 813–827. https://doi.org/10.1038/nrd4333
113. Huang, Y., Gao, X., & Chen, J. (2021). Nanotechnology-based drug delivery systems for natural compounds: A review. *Journal of Controlled Release, 336*, 617–636. https://doi.org/10.1016/j.jconrel.2021.07.017
114. Chen, H., Zhang, Z., Wang, L., Huang, Z., Gong, F., Li, X., & Chen, J. (2023). Artificial intelligence in natural product drug discovery: Current status and future perspectives. *Drug Discovery Today, 28*(5), 103583. https://doi.org/10.1016/j.drudis.2023.103583
115. Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Sheridan, A., Pawson, A., Mime, P., Nikandrova, A., Lyons, P., Rawlins, M. D., & Pirmohamed, M. (2022). Drug repurposing: Progress, challenges and recommendations. *Nature Reviews Drug Discovery, 18*(1), 41–58. https://doi.org/10.1038/nrd.2018.168
116. Aggarwal, B. B., Deb, L., & Prasad, S. (2023). Curcumin-loaded nanoparticles: A promising strategy for the treatment of cancer and inflammatory diseases. *Biomedicines, 11*(3), 712. https://doi.org/10.3390/biomedicines11030712
117. Coley, C. W., Barzilay, R., Jaakkola, T. S., Green, W. H., & Jensen, K. F. (2017). Prediction of organic reaction outcomes using machine learning. *ACS Central Science, 3*(5), 434–443. https://doi.org/10.1021/acscentsci.7b00064

118. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., Bridgland, A., Meyer, C., Kohl, S. A. A., Ballard, A. J., Cowie, A., Romera-Paredes, B., Nikolov, S., Jain, R., Adler, J., &Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature, 596*(7873), 583–589. https://doi.org/10.1038/s41586-021-03819-2
119. Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., Wertheim, H. F., Sumpradit, N., & Cars, O. (2013). Antibiotic resistance: The need for global solutions. The Lancet Infectious Diseases, 13(12), 1057–1098. https://doi.org/10.1016/S1473-3099(13)70318-9
120. De Clercq, E., & Li, G. (2016). Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29(3), 695–747. https://doi.org/10.1128/CMR.00102-15

Access this Article in Online	
Quick Response Code	Website: www.ijarm.com
	Subject: Phytochemistry
DOI:10.22192/ijamr.2026.13.07.004	

How to cite this article:
Venkatajothi Ramarao, Seethalakshmi Illanchezian. (2026). The Convergence of Phytochemistry, Nanotechnology, and Artificial Intelligence in Drug Discovery. Int. J. Adv. Multidiscip. Res. 13(7): 60-75.
DOI: http://dx.doi.org/10.22192/ijamr.2026.13.07.004